Literature DB >> 32556342

Dupilumab Treatment in Two Patients with Cutaneous T-cell Lymphomas.

Ingrid Lazaridou1, Caroline Ram-Wolff, Jean-David Bouaziz, Edouard Bégon, Maxime Battistella, Jacqueline Rivet, Marie Jachiet, Martine Bagot, Adèle de Masson.   

Abstract

Entities:  

Keywords:  Sezary syndrome; mycosis fungoides; pruritus; dupilumab

Mesh：

Substances：

Year:  2020        PMID： 32556342      PMCID： PMC9234988          DOI： 10.2340/00015555-3576

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


× No keyword cloud information.
  6 in total

1.  Diagnosis of Mycosis Fungoides Following Administration of Dupilumab for Misdiagnosed Atopic Dermatitis.

Authors:  Takahito Chiba; Takuya Nagai; Shin-Ichi Osada; Motomu Manabe
Journal:  Acta Derm Venereol       Date:  2019-07-01       Impact factor: 4.437

2.  Clinical severity measures and quality-of-life burden in patients with mycosis fungoides and Sézary syndrome: comparison of generic and dermatology-specific instruments.

Authors:  C M Herbosa; Y R Semenov; A R Rosenberg; N Mehta-Shah; A C Musiek
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-01-30       Impact factor: 6.166

3.  Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

Authors:  Eric L Simpson; Thomas Bieber; Emma Guttman-Yassky; Lisa A Beck; Andrew Blauvelt; Michael J Cork; Jonathan I Silverberg; Mette Deleuran; Yoko Kataoka; Jean-Philippe Lacour; Külli Kingo; Margitta Worm; Yves Poulin; Andreas Wollenberg; Yuhwen Soo; Neil M H Graham; Gianluca Pirozzi; Bolanle Akinlade; Heribert Staudinger; Vera Mastey; Laurent Eckert; Abhijit Gadkari; Neil Stahl; George D Yancopoulos; Marius Ardeleanu
Journal:  N Engl J Med       Date:  2016-09-30       Impact factor: 91.245

4.  Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.

Authors:  Claus Bachert; Joseph K Han; Martin Desrosiers; Peter W Hellings; Nikhil Amin; Stella E Lee; Joaquim Mullol; Leon S Greos; John V Bosso; Tanya M Laidlaw; Anders U Cervin; Jorge F Maspero; Claire Hopkins; Heidi Olze; G Walter Canonica; Pierluigi Paggiaro; Seong H Cho; Wytske J Fokkens; Shigeharu Fujieda; Mei Zhang; Xin Lu; Chunpeng Fan; Steven Draikiwicz; Siddhesh A Kamat; Asif Khan; Gianluca Pirozzi; Naimish Patel; Neil M H Graham; Marcella Ruddy; Heribert Staudinger; David Weinreich; Neil Stahl; George D Yancopoulos; Leda P Mannent
Journal:  Lancet       Date:  2019-09-19       Impact factor: 79.321

5.  Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients.

Authors:  Maria L Espinosa; Morgan T Nguyen; Amaia Saenz Aguirre; Maria Estela Martinez-Escala; Jane Kim; Christina J Walker; David S Pontes; Jonathan I Silverberg; Jaehyuk Choi; Barbara Pro; Laura B Pincus; Joan Guitart; Xiaolong A Zhou
Journal:  J Am Acad Dermatol       Date:  2020-03-27       Impact factor: 11.527

6.  TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma.

Authors:  Emmanuella Guenova; Rei Watanabe; Jessica E Teague; Jennifer A Desimone; Ying Jiang; Mitra Dowlatshahi; Christoph Schlapbach; Knut Schaekel; Alain H Rook; Marianne Tawa; David C Fisher; Thomas S Kupper; Rachael A Clark
Journal:  Clin Cancer Res       Date:  2013-06-19       Impact factor: 12.531
  6 in total
  3 in total

Review 1.  Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis.

Authors:  Kumi Nakazaki; Mina Yoshida; Yosuke Masamoto; Aya Shinozaki-Ushiku; Masako Ikemura; Teruyoshi Hisamoto; Megumi Yasunaga; Shinichi Sato; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2022-03-30       Impact factor: 2.319

Review 2.  A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis.

Authors:  Masahiro Kamata; Yayoi Tada
Journal:  JID Innov       Date:  2021-07-30

Review 3.  Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas.

Authors:  Karol Kołkowski; Magdalena Trzeciak; Małgorzata Sokołowska-Wojdyło
Journal:  Int J Mol Sci       Date:  2021-12-13       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.